Financhill
Back

Prime Medicine Quote, Financials, Valuation and Earnings

Prime Medicine Price Quote

$4.12
+0.14 (+3.52%)
(Updated: September 19, 2024 at 12:05 PM ET)

Prime Medicine Key Stats

Sell
20
Prime Medicine (PRME) is a Sell

Day range:
$3.90 - $4.23
52-week range:
$3.47 - $12.45
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.43%

Volume:
831K
Avg. volume:
573K
1-year change:
-66.55%
Market cap:
$477.7M
Revenue:
$0
EPS:
$-2.17

How Much Does Prime Medicine Make?

Data Unavailable

Is Prime Medicine Growing As A Company?

Data Unavailable

Prime Medicine Stock Price Performance

  • Did Prime Medicine Stock Go Up Last Month?
    Prime Medicine share price went down by -6.13% last month
  • Did PRME's Share Price Rise Over The Last Year?
    PRME share price fell by -66.55% over the past 1 year

What Is Prime Medicine 52-Week High & Low?

Prime Medicine Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Prime Medicine?

  • How Much Debt Does Prime Medicine Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Prime Medicine Have?
    Cash and short term investments quarterly total is $162.9M
  • What Is Prime Medicine’s Book Value Per Share?
    Book value per share is 1.64

Is Prime Medicine Cash Flow Positive?

  • What Is PRME Cash Flow From Operations?
    Cash flow from operations (TTM) is -$196.2M
  • What Is Prime Medicine’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $157.9M
  • What Is Prime Medicine’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$26.6M

Prime Medicine Return On Invested Capital

Data Unavailable

Prime Medicine Earnings Date & Stock Price

Prime Medicine Competitors

  • Who Are Prime Medicine's Competitors?
    Below is a list of companies who compete with Prime Medicine or are related in some way:
    • Design Therapeutics Inc (DSGN)
    • Larimar Therapeutics Inc (LRMR)
    • PTC Therapeutics Inc (PTCT)
    • Solid Biosciences Inc (SLDB)
    • Voyager Therapeutics Inc (VYGR)

Prime Medicine Dividend Yield

Prime Medicine Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -18.85%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 7
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 13.45
Upside from Last Price: 238.05%

Major Shareholders

  • How many PRME shares are owned by institutional investors?
    91.6M PRME shares are owned by institutional investors
  • How many PRME shares are owned by insiders?
    3.5M PRME shares are owned by insiders